EQS-News

Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome - Seite 4

Chairman of the Board
Mail: [e-mail]
www.relieftherapeutics.com

AdVita Lifescience GmbH
Wolfgang Hoppe
Chief Executive Officer
Mail: [e-mail]
www.advita-lifescience.com FOR MEDIA/INVESTOR INQUIRES:
MC Services AG
Anne Hennecke / Brittney Sojeva
Mail: [e-mail]
Tel.: [phone]

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether the phase 2 clinical trial described above that is being undertaken by Prof. Leuppi will be successful; (ii) whether the FDA will approve an application for emergency use authorization for IV RLF-100 if such an application is submitted to the FDA by Relief's collaboration partner in the United States; (iii) whether further development of RLF-100 for COVID-19 lung injuries or other diseases will be successful, (iv) whether the proposed merger between Relief and AdVita will be completed; (v) such other risks as are disclosed in Relief's public reporting, could adversely affect Relief. Relief is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 

---

End of Media Release

---

Language:	English
Company:	RELIEF THERAPEUTICS Holdings AG
	Avenue de Sécheron 15
	1202 Genève
	Switzerland
E-mail:	[e-mail]
Internet:	https://relieftherapeutics.com
ISIN:	CH0100191136
Listed:	SIX Swiss Exchange
EQS News ID:	1187401